Chicago, IL, United States
Chicago, IL, United States

Time filter

Source Type

An air treatment device having a plasma generator electrostatic precipitator assembly, is provided. The assembly includes an electrostatic precipitator configured to charge airborne particles in the vicinity of the electrostatic precipitator to provide charged airborne particles, and a plasma generator positioned in proximity to the electrostatic precipitator and configured for cooperation with the electrostatic precipitator. The plasma generator is configured to discharge plasma and provide an inactivation zone in the region of the plasma generator operable to inactivate airborne particles. The air treatment device includes means for directing the charged airborne particles generated by the electrostatic precipitator into the inactivation zone such that the air treatment device is adapted to generate charged airborne particles and then immediately, to direct the charged airborne particles into the inactivation zone so as to expose the charged airborne particles to plasma in the inactivation zone.


Patent
Novaerus | Date: 2015-04-03

A coil assembly for generating plasma, is disclosed. The coil assembly includes a cylindrical coil having a cylindrical inner mesh, a cylindrical outer mesh and a cylindrical dielectric separating the inner and outer meshes, an insulating stand at each of the first and second end of the cylindrical coil configured for mounting the cylindrical coil in an elevated position, wherein supply of voltage to the inner and outer meshes generates plasma which is discharged from the outer mesh.


Patent
Novaerus | Date: 2015-07-22

A coil assembly for generating plasma, is disclosed. The coil assembly includes a cylindrical coil having a cylindrical inner mesh, a cylindrical outer mesh and a cylindrical dielectric separating the inner and outer meshes, an insulating stand at each of the first and second end of the cylindrical coil configured for mounting the cylindrical coil in an elevated position, wherein supply of voltage to the inner and outer meshes generates plasma which is discharged from the outer mesh.


Trademark
Novaerus | Date: 2014-10-28

Apparatus, installations and systems for disinfecting, sanitising and sterilising; air treatment equipment; air purification equipment; air purification machines; plasma generators for the treatment of air; parts and fittings for all the aforesaid goods. Air purification services; air treatment services; Rental of air purification apparatus.


Trademark
Novaerus | Date: 2014-05-05

Plasma field technology units used to eradicate airborne pathogens.


Trademark
Novaerus | Date: 2014-10-02

Apparatus, installations and systems for disinfecting, sanitising and sterilising; air treatment equipment; air purification equipment; air purification machines; plasma generators for the treatment of air; parts and fittings for all the aforesaid goods. Air purification services; air treatment services; Rental of air purification apparatus.


An air treatment device having a plasma generator electrostatic precipitator assembly, is provided. The assembly includes an electrostatic precipitator configured to charge airborne particles in the vicinity of the electrostatic precipitator to provide charged airborne particles, and a plasma generator positioned in proximity to the electrostatic precipitator and configured for cooperation with the electrostatic precipitator. The plasma generator is configured to discharge plasma and provide an inactivation zone in the region of the plasma generator operable to inactivate airborne particles. The air treatment device includes means for directing the charged airborne particles generated by the electrostatic precipitator into the inactivation zone such that the air treatment device is adapted to generate charged airborne particles and then immediately, to direct the charged airborne particles into the inactivation zone so as to expose the charged airborne particles to plasma in the inactivation zone.


News Article | May 2, 2013
Site: www.wired.com

There has not been one significant development in infection control since the late 19th Century. That statement may at first seem ridiculous, especially when you consider the remarkable advancements in medical science and technology across so many areas: cancer treatment, organ transplants, prenatal care, just to name a few. However, when it comes to preventing the spread of increasingly dangerous and costly Healthcare Acquired Infections (HAIs), we have reached the point of diminishing returns. Infection rates are no longer decreasing; to the contrary, recent studies show consistent increases over the last decade. Each year in the U.S. alone, HAIs affect nearly 2 million people and add billions of dollars to healthcare costs. HAIs kill more people annually than breast cancer, prostate cancer and automobile accidents combined. As bacteria become more resistant to traditional medicines and procedures, technology must play a role in their eradication. In 1867, the British surgeon Joseph Lister began using carbolic acid as an antiseptic in surgical procedures, significantly reducing mortality rates from infection by 30 percent within a decade. Before Lister introduced sterile surgery, a patient could undergo a procedure successfully only to die from a postoperative infection known as ward fever. In the mid-to-late 19th Century, a number of infection control protocols were developed and adopted, and are still vigorously enforced today: hand-washing, using heat to sterilize surgical instruments, and surgical masks. Mankind won some significant battles against infectious diseases, including the eradication of tuberculosis. But in the mid-20th Century, bacteria started fighting back. In 1947, only a few years after mass production of penicillin began, Staphylococcus aureus (“Staph aureus” or a “Staph infection”) is discovered, one of the earlier bacteria in which penicillin resistance was found. In 1961, Methicillin-resistant Staphylococcus aureus (MRSA) was first detected in Britain. Half of all S. aureus infections in the U.S. today are resistant to penicillin, methicillin, tetracycline and erythromycin. More recently, we have seen worldwide outbreaks of infectious diseases such as H5N1 (“avian flu”), severe acute respiratory syndrome (SARS), and H1N1 (“swine flu”). Just last month, the Centers for Disease Control and Prevention (CDC) issued a warning around the growing threat of “nightmare superbugs” that are untreatable because they are resistant to even the most powerful antibiotics. The CDC reports this class of superbug, called Carbapenem-resistant Enterobacteriaceae (CRE), has been found only in nursing homes and hospitals. The data shows about four percent of acute-care hospitals, and 18 percent of long-term acute care hospitals in America, reported at least one case of dangerous CRE bacteria, which are germs that are resistant to most ‘last-resort’ antibiotics. Standard HAI prevention practices, again many of which date back to the 19th Century, include: -Requiring staff to wash their hands after each patient examination and ensure hand hygiene stations are numerous and easily accessible; -Minimizing use of invasive devices, such as catheters; Not only have these traditional methods reached the point of diminishing returns, but so too have antibiotics, which are over-prescribed to the point that they’re actually helping bacteria grow stronger and more virulent. A recent study by the Centers for Disease Control and Prevention (CDC), reported in the New England Journal of Medicine, found that four out of five Americans received an antibiotic prescription in 2010. That amounts to 258 million courses of the drugs within a population of 309 million. The CDC also estimates that half of these prescriptions were not necessary. That’s especially worrisome because the improper use of antibiotics can spread antibiotic resistance. The bugs the drugs are meant to fight are getting stronger and stronger, while at the same time our supply of antibiotics that can fight these more powerful bacteria is becoming more and more limited. HAIs consume resources, prolong patients’ hospital stays, and typically are only partially reimbursed. The CDC in a March 2009 report on the direct medical costs of HAIs, estimates that $35.7 to $45 billion in 2007 dollars is added to the nation’s annual healthcare costs to treat these infections. Hospitalized patients may be covered by Medicare and Medicaid, which in most cases reimburse fixed amounts based on diagnosis. The hospital must absorb the additional costs associated with HAIs, while the HAIs simultaneously prevent the hospital from taking new admissions with reimbursable conditions. In addition to revenue loss, there are hidden costs and lost financial opportunities associated with HAIs. When patients are brought back to the operating room for an incision and drainage of a postsurgical site infection, the surgical suite and the OR team are required, so new cases cannot be scheduled. Additionally, primary procedures are often reimbursed at a higher rate than follow-up procedures. The main transmission routes of microorganisms in hospitals have been identified as contact, droplet, airborne, common vehicle, and vectorborne. Standard practices such as hand-washing, frequent bedding changes and strong disinfectant are proving to be ineffective against preventing the spread of these microorganisms. The World Health Organization (WHO) identifies that contact, droplet and airborne are the most important of these transmission routes in hospitals and that additional safety measures must be considered to prevent the transmission of infections in healthcare facilities. The CDC has adopted the term “aerial dissemination” to define the airborne transmission of infectious agents. “Aerial dissemination” describes particles entering the air for a short time – even for only a few minutes — and then falling onto exposed surfaces. Particles may become disturbed via various hospital ward activities such as floor polishing or bed making. When these particles land, they can either infect patients directly or indirectly through the contamination of clinically important surfaces. When it comes to preventing aerial dissemination, technology can accomplish what medicine and standard HAI prevention practice cannot: eradicate airborne and surface pathogens and significantly reduce microbial surface counts. My company, Novaerus, has developed a small system that creates a plasma field that generates billions of particles – UV photons, electrons, ions and neutral particles. These particles are short lived and are continuously replenished. This plasma field uses a multi-faceted plasma sterilization technique that is uniquely destructive to all microorganisms. By placing a unit in a patient’s room or a common area, the destructive effect on microorganisms is total and immediate; with viral kill rates near theoretical perfection (99.9999999999%) and reduces microbial surface counts by up to 68 percent. Other companies have developed technologies that create hydrogen peroxide-based fogs or vapors to supplement room surface disinfection. The droplets fill the room and are drawn into every nook, crevice and corner, reaching surfaces that regular cleaning and disinfecting cannot. This reduces the risk of cross-contamination of infectious diseases associated with using a rag, wipe or sponge. The CDC estimates that as much as $31.5 billion of the $45 billion annual direct cost of HAIs could be saved with an effective infection program. Reducing HAI damage to the hospitals’ operating budget can also reduce legal liability. The public’s demand for accountability for public safety has increased, giving health care facilities the advantage of more leverage as they represent best practices. These best practices should include the implementation of technology solutions that supplement best practices, to prevent the spread of infectious diseases via the air, surfaces and person-to-person direct contact. Kevin Maughan is the chief executive officer of Novaerus.


News Article | November 14, 2016
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Today, Novaerus and their local strategic partner Vinamedical recognized the introduction of Irish-based Novaerus technology in Vietnam with a signing ceremony at the Presidential Palace in Hanoi.

Loading Novaerus collaborators
Loading Novaerus collaborators